25 February 2025
Fuse Vectors secures 5.2m USD in pre-seed funding to advance cell-free gene therapy technology led by HCVC
Fuse Vectors has closed a successful pre-seed financing round led by HCVC to accelerate its cell-free AAV technology to revolutionize gene therapy with scalable, high-quality viral vector development. This funding, alongside early support from BioInnovation Institute, EIFO and Innovation Fund, enables the advancement of the technology, development of innovative gene therapies and forging of strategic partnerships with pharma, biotech and academia.
Read the full coverage on Forbes here.
4 November 2024
Fuse Vectors wins grand prize in Merck's 2024 EMEA Advanced Biotech Grant
We are thrilled that Fuse Vectors has won the Merck's EMEA Advanced Biotech Grant! This prestigious recognition, announced on the first day of Bio-Europe, highlights our innovative approach and dedication to advancing biotechnology. We extend our heartfelt thanks to Merck Life Science for this honor and for organizing the grant and Bio-Europe. For more details, check out our LinkedIn post below!
10 October 2024
Fuse Vectors: Our journey since stealth
Since emerging from stealth mode, Fuse Vectors has achieved several thrilling milestones. From joining the prestigious NOME Mentoring Network to presenting at key industry events and being selected as a finalist for the Merck Advanced Biotech Grant, our journey has been nothing short of remarkable.
We invite you to read more about our recent achievements and see some memorable moments on our LinkedIn post here.
29 January 2024
Fuse Vectors emerges from stealth at BII's Demo Day 2024
We are thrilled to announce our emergence from stealth mode at the BioInnovation Institute's Demo Day, where we unveiled our groundbreaking gene therapy AAV development platform.
Special thanks to the companies which have supported us through this journey, and to our incredible team for making this possible.
Stay tuned for more! For details, check out our LinkedIn post here.